584
Participants
Start Date
September 30, 2005
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Trastuzumab
Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
Fluorouracil
800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
Cisplatin
80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
Capecitabine
1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Lima
Lima
Changhua
Kaohsiung City
Cape Town
Sydney
Herlev
Leuven
Melbourne
Milton
Durban
Braga
Odense
Adelaide
Kurralta Park
Perth
Cape Town
Faro
San José
Marseille
Mexico City
Caen
Girona
Madrid
Brest
Udine
Tampere
Istanbul
Izmir
Izmir
Valencia
Parma
Guadalajara
Valencia
Florence
Reims
Trier
Mainz
Witten
Lille
Ancona
Monterrey
Strasbourg
Colmar
Heidelberg
Rouen
Napoli
München
Mérida
Beijing
Beijing
Beijing
Beijing
Moscow
Moscow
Moscow
Moscow
Yaroslavl
Ivanovo
Saint Petersburg
Saint Petersburg
Saint Petersburg
Shanghai
Shanghai
Shanghai
Shanghai
Shanghai
Shanghai
Nanjing
Jiangsu
Suzhou
Ryazan
Mumbai
Kazan'
Wuhan
Samara
Ufa
Guangzhou
Guangdong
Yekaterinburg
Kochi
Barretos
Rio de Janeiro
São Paulo
São Paulo
San José
Panama City
Callao
Seoul
Istanbul
Guatemala City
Hyderabad
New Delhi
Roma
Aichi
Chiba
Ehime
Fukuoka
Hyōgo
Nagano
Osaka
Osaka
Saitama
Saitama
Shizuoka
Tochigi
Tokyo
Tokyo
Tokyo
Yamagata
Mexico City
Coimbra
Guimarães
Lisbon
Lisbon
Porto
Porto
Porto
Chelyabinsk
Buchun
Bundang City
Daegu
Goyang-si
Pusan
Seoul
Seoul
Seoul
Seoul
Seoul
Barcelona
Barcelona
Barcelona
Taipei
Shhiye, Ankara
Birmingham
Denbigh
Dundee
Glasgow
Manchester
Metropolitan Borough of Wirral
Weston-super-Mare
Wolverhampton
Collaborators (1)
Chugai Pharmaceutical
INDUSTRY
Hoffmann-La Roche
INDUSTRY